Screener
Regenxbio RGNX Abb Vie For Development Milestone — Billed Contract Receivables
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:BilledContractReceivables.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current accounts receivable: | ||
| Billed to AbbVie for development milestone | $100,000 | — |
| Billed to other customers | 385 | 557 |
| Unbilled Novartis royalties | 4,124 | 23,806 |
| Unbilled Nippon Shinyaku services | 2,222 | 1,997 |
| Other unbilled | 23 | 19 |
| Current accounts receivable | 106,754 | 26,379 |
| Non-current accounts receivable: |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's abb vie for development milestone — billed contract receivables?
- Regenxbio (RGNX) reported abb vie for development milestone — billed contract receivables of $100M in Q2 2026.
- What does abb vie for development milestone — billed contract receivables mean?
- This metric represents the outstanding balance of contractually earned development milestone payments that have been invoiced to a strategic partner but not yet collected. It serves as a key indicator of the company's progress in achieving specific clinical or regulatory milestones within a collaborative research and development agreement. Monitoring this balance provides insight into the timing of cash inflows related to partnership-driven revenue recognition.
Ask your AI about Regenxbio's abb vie for development milestone — billed contract receivables.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude